Recurrent Stage III Ovarian Cancer Complicated by Severe Kidney Injury
This ovarian cancer diagnosis at a glance
- Stage at diagnosis
- Stage III
- Sex
- female
- Treatment
- surgery, chemotherapy, targeted therapy and clinical trial
- Outcome
- In Memory
Treatment course, step by step
- Initial treatment included optimal debulking surgery followed by carboplatin and paclitaxel and then 4 cycles of intraperitoneal cisplatin.
- After progression, she entered a phase II trial of pegylated liposomal doxorubicin and bevacizumab.
- Later progression was treated with gemcitabine, then paclitaxel, and subsequently carboplatin.
What happened, in summary
A 71-year-old woman had undergone optimal debulking surgery for Stage III high-grade papillary serous ovarian cancer at age 64. She received carboplatin and paclitaxel followed by 4 cycles of intraperitoneal cisplatin.
When the cancer progressed 6 months later, she entered a phase II trial using pegylated liposomal doxorubicin with bevacizumab. Over more than a year, her kidney function gradually worsened and she developed proteinuria and hypertension. A later rise in CA-125 and abdominal pain led to gemcitabine, but worsening kidney function, shortness of breath, and edema required hospitalization. Kidney biopsy showed thrombotic microangiopathy with chronic damage.
Her symptoms improved somewhat after treatment was stopped, but the ovarian cancer progressed in the abdomen. Paclitaxel and then carboplatin were used for further treatment. In May 2011, she developed seizures, encephalopathy, and lower-extremity ischemia and was hospitalized. She died 1 week later. The case highlights severe kidney complications during prolonged treatment for recurrent ovarian cancer.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 3 Ovarian Cancer 35 stories
- Bevacizumab for Ovarian Cancer 19 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer